What is the price-to-earnings ratio of IGC Pharma?
The price-earnings ratio of IGC Pharma is currently 22.2.
IGC Pharma P/S 2025
IGC Pharma P/S
22.2
Ticker
IGC
ISIN
US45408X3089
WKN
A1T87A
As of Aug 20, 2025, IGC Pharma's P/S ratio stood at 22.2, a 51.02% change from the 14.7 P/S ratio recorded in the previous year.
The IGC Pharma P/S history
IGC Pharma Aktienanalyse
What does IGC Pharma do?
India Globalization Capital Inc. (IGC) is a Maryland-based company that focuses on the development, marketing, and sale of natural supplements, novel cannabis formulations, food and beverages, and the manufacturing of medical devices. IGC was established in 2005 and initially operated as a construction company in India. However, over the years, the company has evolved into a diversified company based in Maryland due to its innovative products and services. One of IGC's most well-known divisions is IGC Pharma, which focuses on cannabis-based medical formulations and medical devices. IGC holds patent applications for certain cannabis-based products and was one of the first companies to explore the use of cannabis as a potential treatment for Alzheimer's patients. In collaboration with the Institute for Medicine and the Origins of Infancy at the University of Maryland, IGC developed a novel THC-based medication for the treatment of spasms, pain, and other symptoms in multiple sclerosis patients. IGC has also developed the "Hyalolex" product, which is made from specific cannabinoids such as CBD. This preparation is available in Germany under the trade name "Cannabidiol Hexal." Hyalolex is available as a dietary supplement and has been proven effective in improving memory performance, attention, and cognitive abilities in Alzheimer's patients. IGC also operates the IGC Nutraceuticals division, which focuses on the manufacturing and marketing of high-quality natural products. These include vitamins, minerals, dietary supplements, and natural herbal supplements that promote physical and mental well-being and support healthy bodily processes. Some of IGC Nutraceuticals' products include Saffron for Depression Relief, the calcium and magnesium formulation, and Bharat Diagnostics. IGC will continue to invest in various fields, including cannabis-based pain relief, dementia treatments, electrochemical energy storage, and the manufacturing of devices that utilize natural resources such as coal and ore. Overall, IGC has become a diversified company that focuses on a variety of industries. IGC has been a pioneer in the cannabis industry and has gained a good reputation through innovative formulations and patents. By expanding into new industries and investing in new technologies, IGC will continue to stay at the forefront of innovation and strengthen its position as one of the emerging development companies in today's economy. IGC Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding IGC Pharma's P/S Ratio
IGC Pharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing IGC Pharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating IGC Pharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in IGC Pharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about IGC Pharma stock
How has the price-earnings ratio of IGC Pharma changed compared to last year?
The price-to-earnings ratio of IGC Pharma has increased by 51.02% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of IGC Pharma high compared to other companies?
Yes, the price-to-earnings ratio of IGC Pharma is high compared to other companies.
How does an increase in the price-earnings ratio of IGC Pharma affect the company?
An increase in the price-earnings ratio of IGC Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of IGC Pharma affect the company?
A decrease in the price-earnings ratio of IGC Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of IGC Pharma?
Some factors that influence the price-earnings ratio of IGC Pharma are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does IGC Pharma pay?
Over the past 12 months, IGC Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IGC Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of IGC Pharma?
The current dividend yield of IGC Pharma is .
When does IGC Pharma pay dividends?
IGC Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of IGC Pharma?
IGC Pharma paid dividends every year for the past 0 years.
What is the dividend of IGC Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is IGC Pharma located?
IGC Pharma is assigned to the 'Industry' sector.
Wann musste ich die Aktien von IGC Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of IGC Pharma from 8/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/20/2025.
When did IGC Pharma pay the last dividend?
The last dividend was paid out on 8/20/2025.
What was the dividend of IGC Pharma in the year 2024?
In the year 2024, IGC Pharma distributed 0 USD as dividends.
In which currency does IGC Pharma pay out the dividend?
The dividends of IGC Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The IGC Pharma stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von IGC Pharma
Our stock analysis for IGC Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IGC Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
